Peter A. LeWitt

Peter A. LeWitt publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Peter A. LeWitt sits on this spectrum.

Peter A. LeWitt D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Peter A. LeWitt sits on this spectrum.

Best Publications

• Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.

  Christopher G. Goetz;Barbara C. Tilley;Stephanie R. Shaftman;Glenn T. Stebbins

  7786
  Citations

• Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

  Christopher G. Goetz;Stanley Fahn;Pablo Martinez-Martin;Werner Poewe

  1614
  Citations

• Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial

  R. Holloway;I. Shoulson;K. Kieburtz;M. McDermott

  1262
  Citations

• AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

  Peter A LeWitt;Ali R Rezai;Maureen A Leehey;Steven G Ojemann

  750
  Citations

• Levodopa in the treatment of Parkinson's disease: current controversies.

  C. Warren Olanow;Yves Agid;Yoshi Mizuno;Alberto Albanese

  501
  Citations

• Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

  D. A. Loeffler;J. R. Connor;P. L. Juneau;B. S. Snyder

  434
  Citations

• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  Peter A. LeWitt;Peter A. LeWitt;M. Guttman;James W. Tetrud;Paul J. Tuite

  406
  Citations

• A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains.

  James R. Connor;Brian S. Snyder;Paolo Arosio;David A. Loeffler

  405
  Citations

• Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.

  Peter A. LeWitt

  396
  Citations

• Levodopa for the Treatment of Parkinson's Disease

  Peter A. LeWitt

  380
  Citations

• Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

  Ira Shoulson;David Oakes;Stanley Fahn;Anthony Lang

  343
  Citations

• Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study

  Peter A. LeWitt;Kelly E. Lyons;Rajesh Pahwa

  332
  Citations

• The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  R S Burns;P A LeWitt;M H Ebert;H Pakkenberg

  307
  Citations

• A Randomized, Double-blind, Placebo-Controlled Trial of Subcutaneously Injected Apomorphine for Parkinsonian Off-State Events

  Richard B. Dewey;J. Thomas Hutton;Peter A. LeWitt;Stewart A. Factor

  302
  Citations

• Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

  Mark Stacy;Annette Bowron;Mark Guttman;Robert Hauser

  282
  Citations

• Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement

  Alberto J. Espay;Peter A. LeWitt;Horacio Kaufmann

  276
  Citations

• Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.

  D.A. Loeffler;P.A. LeWitt;P.L. Juneau;A.A.F. Sima

  269
  Citations

• Cognitive impairments in Parkinson's disease: Distinguishing between effort-demanding and automatic cognitive processes

  Herbert Weingartner;Stanley Burns;Rita Diebel;Peter A. LeWitt

  260
  Citations

• Reliability of a new scale for essential tremor

  Rodger Elble;Cynthia Comella;Stanley Fahn;Mark Hallett

  259
  Citations

• TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial.

  C Warren Olanow;Anthony H V Schapira;Peter A LeWitt;Karl Kieburtz

  217
  Citations